Long-term follow-up of patients with locally advanced or metastatic thymic malignancies: The Eastern Cooperative Oncology Group (ECOG) experience.

P. Loehrer,Wei Wang,S. Aisner,P. Bonomi,L. Einhorn,C. Langer,Mark R. Green,R. Livingston,David H. Johnson,Joan H. Schiller
DOI: https://doi.org/10.1200/JCO.2004.22.90140.7050
IF: 45.3
2004-07-15
Journal of Clinical Oncology
Abstract:7050 Background: Chemotherapy is active and appears to prolong survival in patients (pts) with advanced thymic cancer. However, limited data exists about the long-term outcomes after systemic therapy. METHODS To assess this, we reviewed records on 123 pts entered on five prospective ECOG phase II trials conducted from 1982 through 2003; these studies evaluated cisplatin as a single agent or as platinum-based combination chemotherapeutic regimens (i.e. cisplatin, doxorubicin, cyclophosphamide (PAC); cisplatin, ifosfamide, etoposide (VIP); carboplatin, paclitaxel). In 23 pts with Stage III disease, PAC was administered prior to definitive radiotherapy. All pts. had unresectable Stage III or IV, histologically proven thymoma (n=111) or thymic carcinoma (n=12) without previous systemic chemotherapy. Pretreatment characteristics included a median age of 50 yrs, M:F = 75:48, PS 0-1 = 83% and prior radiation therapy in 31%. RESULTS Overall, 46 (39%) pts. had an objective response (PR or CR), 46 had stable disease while the remainder had progression or were inevaluable for response. Combination regimens were associated with a higher objective response rate (p<0.0001) and improved overall survival (p=0.035) compared to single agent, cisplatin. Pts with thymic carcinoma were associated with a poorer response rate (p=0.047) and PFS (p=0.014) and a trend towards worse OS (p=0.064) than pts with thymoma. [Figure: see text] Conclusions: 1) Combination chemotherapy produces high response rates with some durable remissions observed in pts with thymoma. 2) Thymic carcinoma is associated with a worse therapeutic outcome than thymoma. 3) The majority of patients with unresectable thymic malignancies still progress and novel treatments are clearly needed. [Table: see text].
What problem does this paper attempt to address?